Metabolomic analysis links weight-loss changes to disease-specific outcomes

Researchers integrated mass spectrometry and nuclear magnetic resonance metabolomic profiles from the DiRECT structured-diet trial and the By-Band-Sleeve bariatric-surgery trial with Mendelian randomisation (MR) estimates of lifetime BMI effects on metabolites. They then used a two-sample MR framework to examine associations between genetically instrumented weight-loss-associated metabolites and heart failure, osteoarthritis and kidney cancer. The analysis identified 242 metabolites consistently altered across the two interventions, mainly lipids, lipoproteins and amino acids; most showed concordant associations with lifetime BMI in MR.

Associations varied by outcome. For heart failure, LDL measures were associated with increased risk, while HDL cholesterol-enrichment traits were associated with lower risk; markers of dysfunctional HDL remodelling were associated with increased risk. Lipoprotein associations with osteoarthritis ran in the opposite direction to those for heart failure, with additional signals involving glycine metabolism. The metabolite signature showed limited associations with kidney cancer: only 5-methyluridine and ursodeoxycholate were identified.

The findings suggest that adiposity-related metabolic changes are not uniformly associated with different obesity-linked diseases. The authors note that residual horizontal pleiotropy may affect the genetic analyses and that rank-normalised metabolite measures limit direct physiological interpretation. The study reports associations and does not establish that modifying these metabolites will alter disease risk.